Genenta Science S.p.A. (NASDAQ:GNTA) Short Interest Down 26.5% in February

Genenta Science S.p.A. (NASDAQ:GNTA) was the recipient of a significant drop in short interest in February. As of February 15th, there was short interest totalling 2,500 shares, a drop of 26.5% from the January 31st total of 3,400 shares. Based on an average daily volume of 10,500 shares, the short-interest ratio is currently 0.2 days.

Institutional Investors Weigh In On Genenta Science

An institutional investor recently bought a new position in Genenta Science stock. Citadel Advisors LLC bought a new stake in Genenta Science S.p.A. (NASDAQ:GNTA) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 11,167 shares of the company’s stock, valued at approximately $46,000. Citadel Advisors LLC owned approximately 0.06% of Genenta Science as of its most recent SEC filing. Institutional investors own 15.13% of the company’s stock.

Genenta Science Price Performance

Shares of NASDAQ GNTA traded up $0.10 during midday trading on Tuesday, reaching $3.81. 4,051 shares of the company’s stock traded hands, compared to its average volume of 8,370. The stock’s 50 day simple moving average is $4.20 and its 200-day simple moving average is $4.56. Genenta Science has a one year low of $2.20 and a one year high of $7.28.

Genenta Science Company Profile

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.